Pfizer Files Supplemental Proxy Materials
Ticker: PFE · Form: DEFA14A · Filed: Apr 10, 2025 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | DEFA14A |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-communication, sec-filing
Related Tickers: PFE
TL;DR
Pfizer sent an email to shareholders, filing supplemental proxy docs. No new fee.
AI Summary
Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 10, 2025, indicating it sent a form of email to certain shareholders. This filing is a supplement to their proxy statement and does not require a new filing fee, as a fee was either not required or paid previously.
Why It Matters
This filing provides an update to shareholders regarding communications and ensures compliance with SEC proxy solicitation rules.
Risk Assessment
Risk Level: low — This is a routine supplemental filing for a proxy statement, not indicating any new or unusual risks for the company.
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- April 10, 2025 (date) — Filing date and email distribution date
- 66 HUDSON BOULEVARD EAST (address) — Pfizer's business and mailing address
- NEW YORK (location) — City for Pfizer's address
- 10001-2192 (zip_code) — Zip code for Pfizer's address
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically a Definitive Additional Materials proxy statement.
When was this filing made?
The filing was made on April 10, 2025.
Who is the filer?
The filer is Pfizer Inc.
What is the purpose of this filing?
This filing serves as a supplement to the proxy statement and indicates that a form of email was sent to certain Pfizer Inc. shareholders.
Was there a filing fee associated with this document?
No fee was required for this filing, or a fee was paid previously with preliminary materials.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 10, 2025 regarding PFIZER INC (PFE).